Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02860780 |
Title | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer |
Recruitment | Completed |
Gender | both |
Phase | Phase I |
Variant Requirements | Yes |
Sponsors | Eli Lilly and Company |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | DEU |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Carolinas Medical Center | Charlotte | North Carolina | 28204 | United States | Details | |
Sarah Cannon Research Institute SCRI | Nashville | Tennessee | 37203 | United States | Details | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Köln | 50937 | Germany | Details |